Beringer Ingelheim Boehringer Ingelheim

Beringer Ingelheim is a family pharmaceutical company founded in 1885 in Ingelheim (Germany), where the company's headquarters are located.

In 2015, the staff of Beringer Ingelheim around the world was almost 47,500 employees.

Assets

For 2016, Beringer Ingelheim is one of the 20 leading global pharmaceutical companies. The company consists of 145 divisions around the world.

Performance indicators

2018

In 2018, Beringer Ingelheim's sales amounted to about 17.5 billion euros. The company spends almost 3.2 billion euros on research and development, which is 18.1% of sales.

2016

Net sales grew in all areas of activity and amounted to 15.9 billion euros (adjusted for exchange rates: in dollars + 7.3%; in euros: + 7.1%). Of these, 12 billion euros brought sales of prescription drugs, 1.5 billion euros - veterinary division, 613 million euros - contract production and 1.6 billion euros - over-the-counter drugs. This is significantly higher than last year's forecast. Net sales income reached 18.1% due to an increase in operating profit by 27% - up to 2.9 billion euros. The Beringer Ingelheim strategy continues to focus on innovation. In 2016, the company again increased research and development costs by 4% - up to 3.1 billion euros. In addition, in 2016, all planned steps for business development were implemented. An asset exchange deal with Sanofi has been completed, which will strengthen Beringer Ingelheim's position among world leaders in the veterinary drug market. The number of employees of the company in connection with the transaction increased to 50,000.

2015

The fiscal year 2015 was successful for Beringer Ingelheim: the company's net sales grew to 14.8 billion euros (adjusted for the currency exchange rate: + 4.1%; + 11.1% in Euro equivalent).

"We have made many breakthroughs in medicine," Professor Andreas Barner, chairman of the company's Board of Managing Directors, said at an annual press conference. "Also in 2015, we were committed to improving our competitiveness and ensuring further sustainable development."

Excluding the company's generic business, sold at the beginning of 2016, net sales growth, taking into account the adjustment for the currency exchange rate, amounted to 5.3%. With an increase in operating revenue by 6% - up to 2.3 billion euros - income from net sales increased by 15.3%.

Last year was marked by an increase in indicators in all divisions of Beringer Ingelheim. For example, net sales of prescription drugs (not counting generics) - the priority area of ​ ​ Beringer Ingelheim - increased by 4.1%, to 10.7 billion euros, taking into account the adjustment for the exchange rate (+ 11.9% in Euro equivalent). The drug SPIRITA ® remains the best-selling - more than 3.5 billion euros. The company's division developing antidiabetic drugs reached the level of long-term stable development, demonstrating a 49% increase in net sales of its entire product line - up to 1.1 billion euros, taking into account the adjustment for the exchange rate (+ 63.8% in Euro equivalent). The share of PRADAXA ® anticoagulant in total net sales is 1.3 billion euros.

In fiscal year 2015, 10% of Beringer Ingelheim's net sales came from over-the-counter drugs. Thanks to the world-famous products of the company:

• DULCOLAX,
• BUSCOPAN,
• MUCOSOLVAN и
• PHARMATON,

net sales increased by 7.1% to 1.5 billion euros, taking into account the adjustment for the exchange rate (+ 5.3% in euro equivalent).

The veterinary business "Beringer Ingelheim" also showed high results in 2015: net sales growth amounted to 10.5% - up to almost 1.4 billion euros. This direction of business amounted to 9% of the total sales of the company. Sales of the INGELVAC CIRCOFLEX pig vaccine amounted to 281 million euros. This vaccine remains the best-selling drug of the company in the field of veterinary medicine (+ 4.1%, taking into account the adjustment for the exchange rate, + 8.1% in Euro equivalent). Sales of preparations for livestock increased by 12%, taking into account the adjustment for the exchange rate, making this direction the basis for business growth (+ 20% in Euro equivalent). As for pet drugs, the vaccine for dogs DURAMUNE showed a significant increase of 7.5%, taking into account the adjustment for the exchange rate - up to 88 million euros (+ 27.5% in Euro equivalent).

The biopharmaceutical business showed an increase of 15% - up to 576 million euros - thus accounting for 4% of total sales.

PRAXBIND approval in the US and Europe means that Beringer Ingelheim now has a specific agent that neutralizes the anticoagulant effect of the drug PRADAXA. Doctors can use it if necessary in rare critical situations.

In the key area for Beringer Ingelheim - the fight against respiratory diseases - the company has also achieved significant results. New drugs have been registered in a number of countries:

• SPIRIVA
• RESPIMAT for asthma,
• SPIOLTO from chronic obstructive pulmonary disease (COPD) and
• OFEV (in Russia - VARGATEF), used to treat a rare disease - idiopathic pulmonary fibrosis (ILF).

To maintain the status of an innovative company in the future, Beringer Ingelheim has made a number of strategic decisions. For example, the company left the generic business, selling its subsidiary in the USA - Roxane. At the end of 2015, Beringer Ingelheim and Sanofi announced their intention to begin exclusive negotiations on the exchange of assets: the over-the-counter business Beringer Ingelheim for Sanofi's veterinary business. Beringer Ingelheim wants to focus on key areas and thus strengthen its competitive advantage. Another important strategic step was the decision to allocate 0.5 billion euros for the development of a biopharmaceutical center in Vienna (Austria).

"Innovative drugs in the future will be a prerequisite for our development and success," Professor Barner said. For this reason, in the next five years, the company intends to spend almost 11 billion euros on international research activities. Of this amount, 5 billion euros will be allocated for preclinical research and development, and another 1.5 billion euros for the development of cooperation with third-party organizations. As of April 2016, about 50% of all innovative solutions of Beringer Ingelheim at the initial and middle stages of research are the result of close cooperation with external partners - universities and biotechnology companies.

As for the final stages of drug development, Beringer Ingelheim managed to reach an agreement with AbbVie, the purpose of which is world cooperation in the development of two promising active substances developed by Beringer Ingelheim for the treatment of autoimmune diseases, such as psoriasis. In this area, there are still not enough truly effective drugs.

In fiscal year 2016, Beringer Ingelheim expects lower net sales growth compared to 2015. This is due to the general slowdown in the growth rate of the pharmaceutical market. "The results of our work will allow us to take a significantly more confident position in many areas of business in the medium term," said Hubertus von Baumbach, a member of the Board of Directors, who is responsible for the company's finances.

The annual report for 2015 is here.

History

2021: Creation of a consortium for the introduction of quantum technologies in industry

In mid-June 2021 BMW , together with, BASF Boehringer Ingelheim,,,, Bosch,, and Infineon Merck Munich Re SAP Siemens created Volkswagen Quantum Technology and Application Consortium (QUTAC), whose members intend to develop a large number of examples for use in industry to create demand for. According quantum computing to QUTAC, this will accelerate the development of technology in and. Germany To Europe More. here

2020: EAEU countries remit US veterinary vaccines to Russia

The bulk of imports veterinary vaccines and serums Russia from countries EEU are not at all the products of the States members of the Union. Drugs are leading in imports to Russia. USA

According to the results of 2020, the rating of corporations was headed by the American company MSD, the total share of the corporation in deliveries is approaching 73%. In second place - also the representative of the United States - the company "Elanco," which took 12% in the total volume of operations. Closes the top three German "Beringer Ingelheim." According to the results of the year, the company took 10.2% in the overall standings.

2016

Prescription drugs

Market entry of new drugs and significant investment in research and development

In the direction of prescription drugs, the company will continue innovative developments for the treatment of respiratory and cardiovascular diseases, oncology, diseases of the central nervous system, immunology. For example, today Beringer Ingelheim is exploring the possibility of using its drug for the therapy of type 2 diabetes mellitus (T2DM) in the treatment of chronic heart failure in patients with or without T2DM. This year, new research has begun. In the field of oncology, the company studies the effectiveness of one of its drugs in the treatment of mesothelioma - an aggressive form of pleura cancer associated with asbestos exposure.

In the field of biosimilars, Beringer Ingelheim pays special attention to two drugs whose development has reached the final stage: one of them is used in oncology, the second in immunology. The latter is now at the stage of approval by state agencies of the European Union and the United States. In 2019, the company also expects approval of its own drug for the treatment of psoriasis.

In the long term, Beringer Ingelheim will continue to work closely with universities, research institutes and biotechnology companies. "Focusing on research and development is an important element of our strategy," confirms von Baumbach. In 2016, the company again increased research and development costs by 4% - up to 3.1 billion euros.

In general, net sales of prescription drugs - the largest business area of ​ ​ Beringer Ingelheim - increased to about 12 billion euros, that is, by 7.4% adjusted for exchange rates (+ 7.5% in euros). The best sales figures, about 3 billion euros, remain with the drug for the treatment of respiratory diseases.

Sanofi and Beringer Ingelheim unite units

{{main 'Company: Sanofi
}}

Petrovax will be the second platform in the world producing Beringer Ingelheim thrombolytics

Beringer Ingelheim and NPO Petrovax Farm signed an agreement in early summer 2016 to localize the full production cycle of modern drugs for the treatment of cardiovascular diseases.

For Beringer Ingelheim, this is the first localization of this level: the company plans to complete the transfer of technologies, quality control methods and establish a full cycle of production of innovative biotechnological thrombolytics based on NPO Petrovax Farm in the Moscow Region by 2019. The capacity of the production complex will be able to fully satisfy the needs of Russian patients in these drugs.

{{main'Petrovax Farm, NGO
}}

2010: Sales volume 12.6 billion euros

The company's sales in 2010 amounted to about EUR 12.6 billion, 24% of which were reinvested in the largest segment of the company's business - Research and Development of New Drugs.